NANOMEDICINE IN CANCER THERAPY: ADVANCES IN TARGETED DRUG DELIVERY, NANO IMMUNOTHERAPY AND EMERGING THERAPEUTIC STRATEGIES

Limited drug solubility, insufficient tumor accumulation, systemic toxicity, multidrug resistance, and the biological heterogeneity of tumors are some of the key obstacles that cancer therapy still faces. In order to enhance the localization and regulated release of anticancer medicines, the review also looks into passive, active, tumor-microenvironment-responsive, and biomimetic targeting techniques. Additionally highlighted is the potential of nanocarriers to transport nucleic acids, immune-modulating drugs, and combination treatments, especially for boosting anticancer immune responses and overcoming therapeutic resistance. Lastly, new strategies such multifunctional nanocarriers, nucleic acid delivery, biomimetic and exosome-based systems, precision nanomedicine, and theragnostic platforms are explored as possible avenues for cancer treatment in the future.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-10-30
DOI
https://doi.org/10.5281/zenodo.23804233
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NANOMEDICINE IN CANCER THERAPY: ADVANCES IN TARGETED DRUG DELIVERY, NANO IMMUNOTHERAPY AND EMERGING THERAPEUTIC STRATEGIES

Shreshth Singhal, Anvesh Davak, Ravi Kumar, Satish Saini et al.
1 links
Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
article

NANOMEDICINE IN CANCER THERAPY: ADVANCES IN TARGETED DRUG DELIVERY, NANO IMMUNOTHERAPY AND EMERGING THERAPEUTIC STRATEGIES

Shreshth Singhal, Anvesh Davak, Ravi Kumar, Satish Saini, Srashty, Karan Pal
article en

Abstract

Limited drug solubility, insufficient tumor accumulation, systemic toxicity, multidrug resistance, and the biological heterogeneity of tumors are some of the key obstacles that cancer therapy still faces. In order to enhance the localization and regulated release of anticancer medicines, the review also looks into passive, active, tumor-microenvironment-responsive, and biomimetic targeting techniques. Additionally highlighted is the potential of nanocarriers to transport nucleic acids, immune-modulating drugs, and combination treatments, especially for boosting anticancer immune responses and overcoming therapeutic resistance. Lastly, new strategies such multifunctional nanocarriers, nucleic acid delivery, biomimetic and exosome-based systems, precision nanomedicine, and theragnostic platforms are explored as possible avenues for cancer treatment in the future.

Zenodo (CERN European Organization for Nuclear Research)
Jiwaji University (IN), Lakshmibai National Institute of Physical Education (IN), ITM University (IN), Gajara Raja Medical College (IN), Arka Jain University (IN), Raja Balwant Singh College (IN)
Good health and well-being
Openalex Percentile: Top 28%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
NANOMEDICINE IN CANCER THERAPY: ADVANCES IN TARGETED DRUG DELIVERY, NANO IMMUNOTHERAPY AND EMERGING THERAPEUTIC STRATEGIES — Shreshth Singhal, Anvesh Davak, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS